



Georgia: COVID-19 Vaccine Support under the Asia Pacific Vaccine Access Facility

| | | | | | | | | | |
|--|---|--|--|----------------------------|--------------------|--|--|----------------------------|-----------------|
| Project Name | COVID-19 Vaccine Support under the Asia Pacific Vaccine Access Facility | | | | | | | | |
| Project Number | 55195-001 | | | | | | | | |
| Country | Georgia | | | | | | | | |
| Project Status | Approved | | | | | | | | |
| Project Type / Modality of Assistance | Loan | | | | | | | | |
| Source of Funding / Amount | <table border="1"> <tr> <td>Loan 4116-GEO: COVID-19 Vaccine Support under the Asia Pacific Vaccine Access Facility</td> <td></td> </tr> <tr> <td>Ordinary capital resources</td> <td>US\$ 14.40 million</td> </tr> <tr> <td>Loan 4118-GEO: COVID-19 Vaccine Support under the Asia Pacific Vaccine Access Facility</td> <td></td> </tr> <tr> <td>Ordinary capital resources</td> <td>US\$ 600,000.00</td> </tr> </table> | Loan 4116-GEO: COVID-19 Vaccine Support under the Asia Pacific Vaccine Access Facility | | Ordinary capital resources | US\$ 14.40 million | Loan 4118-GEO: COVID-19 Vaccine Support under the Asia Pacific Vaccine Access Facility | | Ordinary capital resources | US\$ 600,000.00 |
| Loan 4116-GEO: COVID-19 Vaccine Support under the Asia Pacific Vaccine Access Facility | | | | | | | | | |
| Ordinary capital resources | US\$ 14.40 million | | | | | | | | |
| Loan 4118-GEO: COVID-19 Vaccine Support under the Asia Pacific Vaccine Access Facility | | | | | | | | | |
| Ordinary capital resources | US\$ 600,000.00 | | | | | | | | |
| Strategic Agendas | Inclusive economic growth Regional integration | | | | | | | | |
| Drivers of Change | Partnerships | | | | | | | | |
| Sector / Subsector | Health - Disease control of communicable disease | | | | | | | | |
| Gender Equity and Mainstreaming | Effective gender mainstreaming | | | | | | | | |
| Description | <p>The project is aligned with the following impacts: (i) stabilize the situation and save lives; and (ii) spread, morbidity, and mortality of COVID-19 reduced and confidence of citizens restored. The project outcome is that the target populations per the NVDP are vaccinated against COVID-19.</p> <p>Output 1. COVID-19 vaccine procured and delivered to designated points. The project will finance procurement and delivery of vaccines through bilateral deals between the government and manufacturers and/or through the COVAX Facility. Procurement through bilateral deals with other countries will be considered, subject to due diligence and necessary approvals. To vaccinate an estimated 0.3 million persons, 0.7 million doses of COVID-19 vaccines (assuming 10% adjustment for wastage) will be delivered to regional warehouses according to the NVDP. The expenditure items under the RRC will include (i) vaccines that meet any of the eligibility requirements of the APVAX policy, including advance payments; (ii) international logistics and related services required to transport vaccines from the place of purchase to regional warehouses; and (iii) ancillary items such as syringes, safety boxes, and other items required to administer the vaccines. The NCDC will be responsible for transporting the vaccine from the regional warehouses to the vaccine administration sites. Before the disbursement of the loan proceeds, MOILHSA shall submit to ADB purchase agreements for the vaccines that comply with APVAX policy requirements.</p> <p>Output 2. Vaccine program implementation capacity strengthened. Under the PIC, the project will support activities that will strengthen (i) the project implementation unit (PIU) under the MOILHSA to help implement and monitor the COVID-19 vaccination program; and (ii) carry out gender mainstreaming activities, which include approving updated budget and guidelines for mobile teams to reach marginalized groups, including women. Additional staff will be hired under the project to augment PIU capacity.</p> | | | | | | | | |
| Project Rationale and Linkage to Country/Regional Strategy | <p>The Government of Georgia reported the country's first COVID-19 case on 26 February 2020, followed by the first wave from September 2020 to February 2021, the second, milder wave beginning in March 2021 and a third wave beginning in June 2021. As of 11 August 2021, Georgia had reported 461,198 confirmed COVID-19 cases and 6,230 deaths. The peak number of daily new confirmed cases was at 6,208 in August 2021 during the third wave, compared with 2,171 during the second wave from March to June 2021. Absolute poverty, measured using the international poverty line (\$1.90 per day), is estimated to increase from 3.8% in 2019 to 5.4% in 2020 because of the effects of COVID-19. The pandemic's impact on poverty is significant because of a large number of self-employed and informal sector workers and migrant workers returning home. Gross domestic product (GDP) declined by 6.2% in 2020 because of the COVID-19 pandemic, compared with 5.0% GDP growth in 2019. The government has noted that any further escalation of COVID-19 will have a serious health and socioeconomic impact and further delay economic recovery. Containing the COVID-19 pandemic with vaccination clearly outweighs the costs, reduces the number of severe COVID-19 cases, and reduces the burden on the health system.</p> | | | | | | | | |
| Impact | Stabilize the situation and save lives COVID-19 spread, morbidity, and mortality reduced, and confidence of citizens restored | | | | | | | | |
| Project Outcome | | | | | | | | | |
| Description of Outcome | Target populations per the NVDP vaccinated against COVID-19 | | | | | | | | |
| Progress Toward Outcome | | | | | | | | | |
| Implementation Progress | | | | | | | | | |
| Description of Project Outputs | COVID-19 vaccine procured and delivered to designated points Vaccine program implementation capacity strengthened | | | | | | | | |
| Status of Implementation Progress (Outputs, Activities, and Issues) | | | | | | | | | |
| Geographical Location | Nation-wide | | | | | | | | |

| Safeguard Categories | |
|--------------------------|---|
| Environment | C |
| Involuntary Resettlement | C |
| Indigenous Peoples | C |

| Summary of Environmental and Social Aspects | |
|--|--|
| Environmental Aspects | |
| Involuntary Resettlement | |
| Indigenous Peoples | |
| Stakeholder Communication, Participation, and Consultation | |
| During Project Design | |
| During Project Implementation | |

| | |
|----------------------------|--|
| Responsible ADB Officer | Ramesh, Kirithi |
| Responsible ADB Department | Central and West Asia Department |
| Responsible ADB Division | CWSS |
| Executing Agencies | Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs (MOILHSA) INFO@MOH.GOV.GE 144, Ak. Tsereteli Ave, Tbilisi 0119 |

| Timetable | |
|---------------------|----------------------------|
| Concept Clearance | - |
| Fact Finding | 05 Jul 2021 to 07 Jul 2021 |
| MRM | 29 Jul 2021 |
| Approval | 24 Sep 2021 |
| Last Review Mission | - |
| Last PDS Update | 01 Oct 2021 |

Loan 4116-GEO

| Milestones | | | | | |
|-------------|--------------|------------------|-------------|---------|--------|
| Approval | Signing Date | Effectivity Date | Closing | | |
| | | | Original | Revised | Actual |
| 24 Sep 2021 | 04 Oct 2021 | 29 Oct 2021 | 31 Oct 2023 | - | - |

| Financing Plan | | Loan Utilization | | | |
|----------------|--------------------------------|----------------------------|------|--------|----------------|
| | Total (Amount in US\$ million) | Date | ADB | Others | Net Percentage |
| Project Cost | 17.10 | Cumulative Contract Awards | | | |
| ADB | 14.40 | 22 Oct 2021 | 0.00 | 0.00 | 0% |
| Counterpart | 2.70 | Cumulative Disbursements | | | |
| Cofinancing | 0.00 | 22 Oct 2021 | 0.00 | 0.00 | 0% |

Loan 4118-GEO

| Milestones | | | | | |
|-------------|--------------|------------------|-------------|---------|--------|
| Approval | Signing Date | Effectivity Date | Closing | | |
| | | | Original | Revised | Actual |
| 24 Sep 2021 | - | - | 31 Oct 2023 | - | - |

| Financing Plan | | Loan Utilization | | | |
|----------------|--------------------------------|----------------------------|------|--------|----------------|
| | Total (Amount in US\$ million) | Date | ADB | Others | Net Percentage |
| Project Cost | 0.60 | Cumulative Contract Awards | | | |
| ADB | 0.60 | 22 Oct 2021 | 0.00 | 0.00 | 0% |
| Counterpart | 0.00 | Cumulative Disbursements | | | |
| Cofinancing | 0.00 | 22 Oct 2021 | 0.00 | 0.00 | 0% |

| | |
|-------------------------|---|
| Project Page | https://www.adb.org/projects/55195-001/main |
| Request for Information | http://www.adb.org/forms/request-information-form?subject=55195-001 |
| Date Generated | 03 November 2021 |

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.